• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ocular surface changes associated with belantamab mafodotin treatment.

作者信息

Ghalibafan Seyyedehfatemeh, Osei Kwaku A, Hoffman James E, Sabater Alfonso L

机构信息

Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.

Department of Medicine, Division of Hematology, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA.

出版信息

Graefes Arch Clin Exp Ophthalmol. 2023 Nov;261(11):3201-3204. doi: 10.1007/s00417-023-06094-1. Epub 2023 May 22.

DOI:10.1007/s00417-023-06094-1
PMID:37212873
Abstract
摘要

相似文献

1
Ocular surface changes associated with belantamab mafodotin treatment.与贝兰他单抗莫福汀治疗相关的眼表变化。
Graefes Arch Clin Exp Ophthalmol. 2023 Nov;261(11):3201-3204. doi: 10.1007/s00417-023-06094-1. Epub 2023 May 22.
2
EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.EMA 审查贝兰他单抗mafodotin（Blenrep）治疗成人复发/难治性多发性骨髓瘤。
Oncologist. 2021 Jan;26(1):70-76. doi: 10.1002/onco.13592. Epub 2020 Nov 23.
3
FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma.FDA 批准概要：贝兰他单抗mafodotin 用于治疗复发或难治性多发性骨髓瘤患者。
Clin Cancer Res. 2022 Nov 1;28(21):4629-4633. doi: 10.1158/1078-0432.CCR-22-0618.
4
Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.在复发/难治性多发性骨髓瘤患者中，针对贝兰他单抗mafodotin 的治疗剂量选择进行暴露-反应分析。
Clin Pharmacol Ther. 2021 Nov;110(5):1282-1292. doi: 10.1002/cpt.2409. Epub 2021 Oct 4.
5
Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography.使用眼前节光学相干断层扫描技术观察贝兰他单抗相关浅层角膜病变中角膜上皮的结构变化。
Am J Ophthalmol Case Rep. 2021 Jun 9;23:101133. doi: 10.1016/j.ajoc.2021.101133. eCollection 2021 Sep.
6
Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.贝兰他单抗mafodotin 治疗多发性骨髓瘤：临床疗效和安全性概述。
Drug Des Devel Ther. 2021 Jun 2;15:2401-2415. doi: 10.2147/DDDT.S267404. eCollection 2021.
7
Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study.DREAMM-2研究中，患者报告的使用贝兰他单抗莫福汀治疗复发/难治性多发性骨髓瘤期间及之后的体验。
Front Oncol. 2023 Dec 7;13:1274659. doi: 10.3389/fonc.2023.1274659. eCollection 2023.
8
Visualization of Keratopathy Associated With the Antibody-Drug Conjugate Belantamab Mafodotin Using Infrared Imaging in Patients With Multiple Myeloma.在多发性骨髓瘤患者中使用红外成像观察与抗体药物偶联物贝兰他单抗莫福汀相关的角膜病变
Cornea. 2025 Feb 1;44(2):196-202. doi: 10.1097/ICO.0000000000003596. Epub 2024 Jun 18.
9
Corneal epithelial changes in a patient treated with belantamab mafodotin.接受贝兰他单抗莫福汀治疗患者的角膜上皮变化
Taiwan J Ophthalmol. 2023 Aug 11;13(3):380-383. doi: 10.4103/tjo.TJO-D-22-00171. eCollection 2023 Jul-Sep.
10
Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma.贝兰他单抗莫福汀的眼部毒性：复发难治性多发性骨髓瘤治疗的肿瘤学视角
Front Oncol. 2021 May 11;11:678634. doi: 10.3389/fonc.2021.678634. eCollection 2021.

引用本文的文献

1
Characterization of Belantamab Mafodotin-Induced Corneal Changes in Patients With Multiple Myeloma.多发性骨髓瘤患者中贝利司他单抗诱导的角膜变化特征
JAMA Ophthalmol. 2025 May 8. doi: 10.1001/jamaophthalmol.2025.1008.

本文引用的文献

1
Toll-like receptors: New targets for multiple myeloma treatment?Toll样受体：多发性骨髓瘤治疗的新靶点？
Biochem Pharmacol. 2022 May;199:114992. doi: 10.1016/j.bcp.2022.114992. Epub 2022 Mar 12.
2
Promising therapeutic approaches for relapsed/refractory multiple myeloma.复发/难治性多发性骨髓瘤的有前途的治疗方法。
Hematology. 2022 Dec;27(1):343-352. doi: 10.1080/16078454.2022.2045724.
3
Belantamab mafodotin associated corneal microcyst-like epithelial changes.贝兰他单抗莫福汀相关的角膜微囊肿样上皮改变。
Am J Ophthalmol Case Rep. 2022 Feb 2;25:101392. doi: 10.1016/j.ajoc.2022.101392. eCollection 2022 Mar.
4
Belantamab Mafodotin-blmf: A Novel Antibody-Drug Conjugate for Treatment of Patients With Relapsed/Refractory Multiple Myeloma.贝兰他单抗莫福汀-blmf：一种用于治疗复发/难治性多发性骨髓瘤患者的新型抗体药物偶联物。
J Adv Pract Oncol. 2022 Jan;13(1):77-85. doi: 10.6004/jadpro.2022.13.1.7. Epub 2022 Feb 1.
5
Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report.应用角膜共聚焦显微镜早期检测贝兰他单抗马妥昔单抗诱导的眼部毒性并相应调整剂量：病例报告。
J Hematol Oncol. 2021 Oct 3;14(1):159. doi: 10.1186/s13045-021-01172-5.